Company Research Report: Infinimmune
Company Overview
- Name: Infinimmune
- Mission: Advancing Whole Human Antibodies for Human Diseases.
- Founded: No information is available.
- Founders: Wyatt McDonnell (CEO & Co-Founder), Lance Hepler (Co-Founder, R&D Team), Mike Gibbons (Co-Founder, R&D Team), Katie Pfeiffer (Co-Founder, R&D Team), David Jaffe (Co-Founder, R&D Team).
- Key People:
- Wyatt McDonnell: CEO & Co-Founder
- Dr. Tim Sullivan: Chief Business Officer
- Lance Hepler: Co-Founder, R&D Team
- Mike Gibbons: Co-Founder, R&D Team
- Katie Pfeiffer: Co-Founder, R&D Team
- David Jaffe: Co-Founder, R&D Team
- Denise Hilton: R&D Team
- Melanie Freeman: R&D Team
- Andrew Hill: R&D Team
- Ringo: Chief Morale Officer
- Headquarters: No information is available.
- Number of Employees: No information is available.
- Revenue: No information is available.
- Known For: Infinimmune is known for developing drugs from complete human antibodies, leveraging its Anthrobody™ platform to discover therapies for autoimmune diseases and cancer.
Products
- Main Product: Anthrobody™ Platform
- Description: The platform focuses on developing complete human antibodies. It involves the discovery, characterization, and validation of antibody drug candidates sourced entirely from human immune systems.
- Key Features:
- Confidence in safety due to reduced immunogenicity, as human-sourced antibodies are recognized as 'self' by the immune system.
- Improved pharmacokinetics, which results in longer half-life and enhanced tissue distribution.
- Enhanced binding specificity and therapeutic effectiveness, maximizing benefits and minimizing off-target effects.
Recent Developments
- New Partnerships & Strategic Appointments:
- Partnership with Grid Therapeutics (January 5, 2024): Infinimmune partnered with Grid Therapeutics to conduct deep sequencing of B cells for oncology drug discovery, focusing on human-derived antibodies for non-small cell lung cancer.
- Appointment of Dr. Tim Sullivan (September 3, 2024): Appointed as Chief Business Officer to oversee corporate and business development initiatives, capitalizing on extensive industry experience.
- Appointment of Dr. Neela Patel (May 15, 2024): Joined the Board of Directors, bringing decades of pharmaceutical and biotechnology expertise.
- Funding:
- Raised $12 million in seed funding on December 6, 2022, to advance the use of human-sourced antibodies in drug design.
- Product Developments:
- Ongoing work with the Anthrobody™ platform continues to refine the discoverability and delivery of potent, safe antibody therapeutics.
Infinimmune remains committed to integrating innovations in biology, chemistry, engineering, and computation to discover drugs uniquely crafted by leveraging naturally occurring, in vivo human antibodies.
Note: For fields with no available data, the report notes "No information is available," ensuring a comprehensive and professional presentation based on provided data.
